Zetia Cost in Mississippi 2026: Cash Price, Medicaid Coverage, and the Cheapest Way to Pay

What Is Ezetimibe and Why Do Mississippi Patients Use It?

Ezetimibe (brand name Zetia) is a cholesterol absorption inhibitor approved by the FDA in 2002 for lowering low-density lipoprotein cholesterol (LDL-C) as an adjunct to diet and, usually, statin therapy. It blocks the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the small intestine, cutting dietary and biliary cholesterol absorption by roughly 50 percent. The standard dose is 10 mg orally once daily, and it can be taken at any time of day with or without food.

Mississippi carries one of the highest cardiovascular disease burdens in the United States. According to the CDC, age-adjusted coronary heart disease death rates in Mississippi consistently rank among the top three states nationally, which makes aggressive LDL-C management clinically significant for a large share of the population [1]. Physicians in Mississippi frequently pair ezetimibe with a moderate- or high-intensity statin when patients cannot tolerate higher statin doses or fail to reach guideline-recommended LDL-C targets on statin monotherapy.

The IMPROVE-IT trial (N=18,144) published in the New England Journal of Medicine in 2015 remains the definitive outcome evidence for ezetimibe. Adding ezetimibe 10 mg to simvastatin 40 mg reduced the composite cardiovascular endpoint (cardiovascular death, major coronary events, or nonfatal stroke) from 34.7 percent to 32.7 percent versus simvastatin alone over a median 7-year follow-up, an absolute risk reduction of 2.0 percentage points (HR 0.936, 95 percent CI 0.89 to 0.99, P<0.001) [2]. The trial enrolled high-risk patients post-acute coronary syndrome, and the benefit was consistent across subgroups including patients with diabetes.

The 2022 ACC/AHA Guideline on the Management of Blood Cholesterol states: "In patients with clinical ASCVD in whom LDL-C remains above goal on maximally tolerated statin therapy, ezetimibe is recommended as the next agent to add." [3] That recommendation places ezetimibe squarely in front of PCSK9 inhibitors from a cost-effectiveness standpoint, especially for Mississippi patients who face coverage gaps on more expensive biologics.

Zetia Price in Mississippi in 2026: Brand vs. Generic

The list price of brand-name Zetia from Merck is approximately $380 per month in 2026. That number is nearly irrelevant for most patients because multiple generic ezetimibe products entered the U.S. market after patent expiration, and cash-pay prices at Mississippi retail pharmacies now sit around $15 per month for a 30-day supply of generic ezetimibe 10 mg [4].

Price variation exists across chains. A GoodRx or RxSaver search in Jackson, MS in mid-2025 showed prices ranging from roughly $11 at Walmart (using the $4 generic program for a 30-day supply) to about $22 at some independent pharmacies without a discount card. The same search returned prices near $14 at CVS and $16 at Walgreens when a free discount coupon was applied. Patients who pay cash should always run a coupon check before accepting the pharmacy's sticker price.

Brand-name Zetia through insurance depends entirely on formulary tier. When it appears at all, Zetia typically lands on Tier 3 or Tier 4, generating copays from $45 to over $100 per month depending on the plan. Generic ezetimibe, by contrast, usually sits on Tier 1 or Tier 2 with copays of $5 to $20.

Merck offers a Zetia Savings Card for commercially insured patients. Eligible patients pay as little as $5 per 30-day prescription, with savings up to $150 per fill. The card is not valid for patients covered by federal or state programs including Medicare, Medicaid, TRICARE, or any government-funded plan. Mississippi residents on commercial plans should visit the Merck savings card portal directly or ask their HealthRX telehealth prescriber to activate the coupon at point of care.

Mississippi Medicaid Coverage for Zetia

Mississippi Medicaid does not cover Zetia, and generic ezetimibe is not listed on the Mississippi Division of Medicaid Preferred Drug List (PDL) as a covered preferred or non-preferred agent for hyperlipidemia in 2026. This is a known coverage gap that disproportionately affects low-income Mississippi residents who carry elevated cardiovascular risk.

Patients on Mississippi Medicaid who need ezetimibe have several options. First, bile acid sequestrants such as cholestyramine are covered and may partially complement statin therapy, though tolerability limits use. Second, a prescriber may submit a prior authorization (PA) request to Mississippi Medicaid citing clinical necessity, though approval rates for non-PDL lipid agents tend to be low without documented statin intolerance. Third, patients can pay the $15 cash-pay price out of pocket, which is low enough that some Medicaid enrollees find it cheaper than navigating PA requirements.

The Affordable Care Act's preventive services mandate (section 2713) requires non-grandfathered private plans to cover USPSTF-recommended preventive statins without cost-sharing for adults aged 40 to 75 with cardiovascular risk factors, but that mandate does not extend to ezetimibe [5]. Mississippi ACA marketplace plans therefore vary widely on ezetimibe coverage.

For Medicaid managed care enrollees in Mississippi (plans administered by Magnolia Health, Molina Healthcare of Mississippi, and UnitedHealthcare Community Plan), formulary status may differ from fee-for-service Medicaid. Patients should call the member services number on their plan card and ask specifically whether generic ezetimibe 10 mg is covered and at what tier.

HealthRX Mississippi Ezetimibe Coverage Decision Framework

Use the following four-step pathway to find the lowest cost for ezetimibe in Mississippi:

1. Check generic cash price first. Run a GoodRx or RxSaver coupon at your target pharmacy. If the price is at or below $15, paying cash may beat your copay.
2. Verify formulary tier. If you carry commercial insurance, ask your plan whether generic ezetimibe (NDC codes vary by manufacturer) is covered. Tier 1 or 2 copays are usually lower than cash price.
3. Apply a manufacturer or PBM coupon. Merck's savings card applies to brand Zetia for commercial patients. SingleCare and RxSaver coupons often apply to generics.
4. Ask about 503A compounding. If you meet clinical eligibility and your prescriber believes compounding is medically appropriate, a licensed Mississippi 503A pharmacy may prepare ezetimibe at a very low or zero copay depending on your plan or cash arrangement.

Is Compounded Ezetimibe Legal in Mississippi?

Yes. Licensed 503A compounding pharmacies in Mississippi may legally prepare ezetimibe for individual patients when a prescriber issues a valid patient-specific prescription. Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies, and Mississippi Board of Pharmacy rules align with federal requirements for compounding of commercially available drugs when a documented clinical rationale exists [6].

Compounded ezetimibe is most often prepared as a capsule at 10 mg, sometimes combined with other lipid-modifying agents (such as berberine or omega-3 fatty acids) in a single capsule when a prescriber orders a combination. The clinical and regulatory important point: compounding a drug that is commercially available requires a valid patient-specific prescription and a documented reason why the commercial product does not meet the patient's clinical need (for example, an excipient allergy or a dose not available commercially).

Cost for compounded ezetimibe at a 503A pharmacy in Mississippi can approach $0 per month when the prescription is covered under certain specialty plan arrangements, though cash-pay compounding fees vary by pharmacy and formulation. Given that generic ezetimibe already costs roughly $15 per month, many patients find the commercial generic the simpler path. Compounding becomes more attractive when a combined formulation is ordered or when a patient has a documented allergy to tablet excipients.

503B outsourcing facilities (FDA-registered, producing larger batches) generally do not compound ezetimibe for individual patients; that remains the domain of 503A pharmacies.

Telehealth Prescribing of Ezetimibe in Mississippi

Mississippi allows telehealth prescribing of ezetimibe. The state participates in the Interstate Medical Licensure Compact, and Mississippi enacted telehealth parity law requiring private insurers to cover telehealth services at the same rate as in-person care for covered benefits. A board-certified physician or nurse practitioner licensed in Mississippi may prescribe ezetimibe after a synchronous audio-video visit or, under certain conditions, an asynchronous store-and-forward encounter [7].

For HealthRX patients in Mississippi, the typical workflow is:

• Complete a digital intake with lipid panel results (ideally from the past 12 months).
• Attend a synchronous video visit with a licensed Mississippi prescriber.
• Receive an ezetimibe prescription sent electronically to your preferred Mississippi pharmacy.
• Apply a discount coupon at the pharmacy to access the $15 cash price.

Prescribers ordering ezetimibe via telehealth still require adequate clinical information to assess cardiovascular risk, confirm the absence of contraindications (severe hepatic impairment is the primary contraindication listed in the FDA label [8]), and set a monitoring plan. Lipid panel follow-up at 6 to 12 weeks after initiation is standard of care per ACC/AHA guidelines.

Which Insurance Plans Cover Ezetimibe in Mississippi?

Coverage varies by plan type and formulary year. Below is a practical breakdown as of 2026.

Commercial employer-sponsored plans. Most large-group plans in Mississippi cover generic ezetimibe at Tier 1 or Tier 2. Blue Cross and Blue Shield of Mississippi, one of the largest commercial insurers in the state, lists generic ezetimibe on its standard formulary. Copays typically range from $5 to $20 per month on generic tiers. Brand Zetia appears at Tier 3 in most BCBS MS plans, with copays from $45 to $90 before deductible.

ACA Marketplace plans. Silver and Gold tier plans on the Mississippi marketplace (Healthcare.gov) generally include generic ezetimibe as a covered generic. Patients should use the plan's formulary search tool at healthcare.gov before enrolling to confirm ezetimibe's tier.

Medicare Part D. Generic ezetimibe is covered under most Mississippi Part D standalone plans and Medicare Advantage prescription drug plans. In 2026, the Inflation Reduction Act's $2,000 out-of-pocket cap provides additional protection for beneficiaries who use multiple medications. The specific tier depends on the plan; patients can use Medicare's Plan Finder at medicare.gov to identify plans that cover ezetimibe at the lowest copay.

Mississippi Medicaid (fee-for-service). Not covered, as noted above.

Medicaid managed care (Magnolia Health, Molina MS, UnitedHealthcare CP). Coverage varies by plan; call member services.

TRICARE. Generic ezetimibe is covered under TRICARE formulary for active duty and retired military in Mississippi.

Side Effects and Drug Interactions Relevant to Mississippi Prescribers

Ezetimibe is generally well tolerated. The most common adverse effects reported in clinical trials include upper respiratory tract infection (occurring in about 4.3 percent of patients in IMPROVE-IT vs. 4.2 percent with placebo), arthralgia, diarrhea, and sinusitis [2]. Myopathy has been reported rarely, most often when ezetimibe is combined with a statin. The FDA label notes that muscle symptoms should prompt creatine kinase (CK) measurement, though routine CK monitoring is not required in asymptomatic patients [8].

Clinically significant drug interactions include:

• Cyclosporine: Ezetimibe AUC increases substantially; use with caution and monitor closely.
• Fibrates (fenofibrate, gemfibrozil): Coadministration increases ezetimibe exposure and raises the theoretical risk of cholelithiasis. Gemfibrozil coadministration is generally discouraged.
• Bile acid sequestrants (cholestyramine): These reduce ezetimibe absorption by roughly 55 percent. Space ezetimibe at least 2 hours before or 4 hours after cholestyramine.
• Warfarin: Ezetimibe does not meaningfully affect warfarin pharmacokinetics based on controlled studies, though the FDA label recommends monitoring INR when ezetimibe is added in patients on warfarin [8].

Pregnancy category considerations are relevant in Mississippi, where reproductive-age women represent a meaningful share of statin-ezetimibe users. Ezetimibe is FDA category X with statins (the combination is contraindicated in pregnancy), and ezetimibe monotherapy has limited human safety data. Prescribers should counsel women of childbearing potential accordingly.

Efficacy Data: What to Tell Mississippi Patients Asking "Does It Really Work?"

The LDL-C lowering effect of ezetimibe 10 mg monotherapy is approximately 18 to 20 percent [9]. Added on top of a statin, ezetimibe produces an incremental LDL-C reduction of roughly 23 to 24 percent beyond what the statin achieves alone, effectively doubling the statin's dose-equivalent LDL-C reduction without doubling the dose-related myopathy risk.

IMPROVE-IT provided the first definitive evidence that LDL-C lowering beyond statin therapy translates to reduced cardiovascular events. The trial's lead finding: each 1 mmol/L (38.7 mg/dL) reduction in LDL-C produces approximately a 20 percent relative risk reduction in major cardiovascular events, consistent with the Cholesterol Treatment Trialists' (CTT) meta-analysis of 170,000 patients [10]. This "lower is better" principle now underpins ACC/AHA guideline recommendations for high-risk patients in Mississippi and nationwide.

For Mississippi patients with diabetes, a pre-specified IMPROVE-IT subgroup analysis (N=4,933 diabetic patients) showed a larger absolute cardiovascular benefit with ezetimibe/simvastatin versus simvastatin alone: 13.5 percent relative risk reduction versus 5.5 percent in non-diabetic patients (P interaction = 0.023) [2]. Given that Mississippi has the second-highest age-adjusted diabetes prevalence in the United States at approximately 16.1 percent of adults (CDC data, 2023), this subgroup finding is directly applicable to a large portion of the state's high-risk cardiology population [1].

As Dr. Christopher Cannon, IMPROVE-IT principal investigator, stated in the accompanying NEJM editorial: "The results provide definitive proof that lowering LDL cholesterol below currently recommended levels with the addition of ezetimibe to statin therapy further reduces cardiovascular risk." [2]

Comparing Ezetimibe to Other Non-Statin LDL-C Agents Available in Mississippi

Mississippi prescribers managing patients who need LDL-C lowering beyond statins have several options besides ezetimibe. A practical comparison helps frame where ezetimibe fits.

PCSK9 inhibitors (evolocumab, alirocumab). These injectable biologics reduce LDL-C by 50 to 60 percent and have cardiovascular outcome trial evidence (FOURIER and ODYSSEY Outcomes, respectively). List price exceeds $5,500 per year. Prior authorization requirements are substantial. For most Mississippi patients, ezetimibe is the appropriate first add-on before a PCSK9 inhibitor is considered.

Inclisiran (Leqvio). A small interfering RNA agent administered by injection twice yearly. Reduces LDL-C by approximately 50 percent. Cost and prior authorization barriers are similar to PCSK9 inhibitors. Outcome data are pending in the ORION-4 trial.

Bempedoic acid (Nexletol). An oral ATP-citrate lyase inhibitor approved in 2020. Reduces LDL-C by approximately 17 to 18 percent. The CLEAR Outcomes trial (N=13,970, NEJM 2023) showed a significant reduction in the four-component MACE endpoint versus placebo in statin-intolerant patients [11]. List price around $250 per month. Generic ezetimibe at $15 per month with a longer evidence base remains more cost-effective for most patients who can tolerate statins.

Bile acid sequestrants. Older agents; LDL-C reduction of 10 to 30 percent depending on dose. Mississippi Medicaid covers some formulations. Gastrointestinal tolerability limits adherence.

The ACC/AHA 2022 guideline recommends adding ezetimibe before escalating to PCSK9 inhibitors or inclisiran based on cost-effectiveness thresholds [3]. At $15 per month, ezetimibe in Mississippi represents exceptional value per mmol/L of LDL-C reduced compared with any alternative.

How to Get the Lowest Possible Price on Ezetimibe in Mississippi Right Now

The cheapest reliable path for most Mississippi residents in 2026 is a 90-day supply of generic ezetimibe 10 mg at Walmart Pharmacy using Walmart's $4/$10 generic program (approximately $10 for 30 days or $15 for 90 days). Verify availability at your local Walmart Pharmacy because formulary participation can vary by store.

The second-cheapest path is a discount coupon (GoodRx, RxSaver, SingleCare) at any major chain. Prices at chains with coupons routinely land between $12 and $20 for a 30-day supply in Mississippi ZIP codes as of mid-2025.

For commercially insured patients, the Merck Zetia Savings Card can bring brand-name Zetia to $5 per fill, though generic ezetimibe at $15 out-of-pocket often remains simpler to access and does not require brand-specific insurance navigation.

Patients receiving care through HealthRX's Mississippi-licensed telehealth platform can receive a prescription and a coupon recommendation in a single visit. The prescriber will default to generic ezetimibe 10 mg unless a clinical reason exists to specify the brand.